MarginsXMarginsX
Home › Markets › Health Care › MGX

Metagenomi Therapeutics Inc. (MGX)

MGX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6800
-1.69% on the day
Market cap
$25.7M
Nano cap
Revenue · 2025
$25.2M
-51.8% on 2024
Net income · 2025
-$87.9M
-348.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2024
SEC CIK0001785279
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$25.2M
Net income-$87.9M
Operating income-$96.0M
Net margin-348.5%
Operating margin-380.9%
Revenue growth-51.8%
Cash$41.7M
Total assets$221.1M
P/E (computed)Net income was not positive
P/S (computed)1.0×

Warning signs

Cash runway
5.2 months
$36.1M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$10K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$36.1M cash; operating cash flow -$20.8M a quarter.Report 2026-09-30
Shares outstanding37,805,669 (2026-11-06).Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $23K, sold $33K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.2M-$21.1M-$19.1M$36.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$27.5M-$19.5M$39.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
$1.2M-$23.1M-$21.2M$25.3MNo debt tags$22.3M10-Q 2026-05-11
Q4 2025
2025-12-31
$3.9M-$22.5M-$23.5M$41.7MNo debt tags$25.2M10-K 2026-03-05
Q3 2025
2025-09-30
$8.7M-$20.4M-$21.3M$32.8MNo debt tags$30.9M10-Q 2026-11-10
Q2 2025
2025-06-30
$8.5M-$19.9M-$21.3M$26.9MNo debt tags$33.8M10-Q 2025-08-12
Q1 2025
2025-03-31
$4.1M-$25.0M-$22.8M$29.2MNo debt tags$45.3M10-Q 2026-05-11
Q4 2024
2024-12-31
$9.6M-$23.4M-$26.3M$27.4MNo debt tags$52.3M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-03-17
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 157 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.4%
1 month-24.5%
3 months-43.7%
Year to date-57.3%
1 year-59.3%
From 52-week high-62.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
CVMCel-Sci Corporation$1.66+29.69%$29.2M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
LONALeonaBio Inc.$3.23-6.92%$30.4M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
BSEMBioStem Technologies Inc.$0.9601-8.56%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier